Sean G. Rudd

PrimPol-A new polymerase on the block.

Pathways controlling dNTP pools to maintain genome stability.

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

SAMHD1 is a barrier to antimetabolite-based cancer therapies.

SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.

With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.

Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.

Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.

Author Correction: Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.

Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Cell Cycle Profiling Reveals Protein Oscillation, Phosphorylation, and Localization Dynamics.

MTH1 Inhibitor TH588 Disturbs Mitotic Progression and Induces Mitosis-Dependent Accumulation of Genomic 8-oxodG.

Development of a chemical probe against NUDT15.

Drug synergy scoring using minimal dose response matrices.

Crystal structures of NUDT15 variants enabled by a potent inhibitor reveal the structural basis for thiopurine sensitivity.